In the first three months of 2007 JSC Grindeks has successfully continued to
increase product manufacturing and sales volumes in accordance to the company's
fast development plans.
Sales of JSC Grindeks in the first three-months of 2007 reached 11.93 millions
of lats, being for 23% more than in the related period in 2006.
Company's earnings before taxes in the first three-month of 2007 reached 6.36
million lats, and in comparison to the respective data in 2006 have grown by
16%.
Amount of net profit in the three months of 2007 reached 1.73 million lats,
with net profit margin - 14.4%.
Sales volumes of finale dosage forms in the first quarter of this year comprise
10.56 million lats, increasing for 18% from the respective period in 2006.
Export of active pharmaceutical ingredients in the 1st quarter of this year
reached 1.27 million lats that exceeds respective period in 2006 for 71%. Thus
Grindeks is increasing export of the active pharmaceutical ingredients, while
securing presence of the company in the Western markets.
Currently research and development structure of the company continues works on
the development of the new products.
Grindeks is the leading pharmaceutical company in the Baltic States
specializing in the manufacturing and sales of heart and cardiovascular,
central nervous system and anti-cancer medications. Its concern consists of
four subsidiary companies in Latvia, Estonia and Russia as well as seven
representative offices. Products of the company are exported to more than 40
countries. Main markets - Baltic States, Russia and other CIS countries, Japan,
USA. Grindeks shares are listed in the Official list of Riga Stock Exchange.
Information was prepared by:
Karlina Jurjeva
JSC Grindeks, Investor relations specialist
Tel:7083241
e-mail :karlina_jurjeva@grindeks.lv
